Physician profile
Eric S Ward
NPI 1194811182
$9,533.17
in general payments reported to CMS, 2019-2025
24 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $1,003 · 2021: $3,506 · 2022: $2,312 · 2023: $905 · 2024: $504 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.59 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $5,130.77 | 2020-2024 | Axonics |
| Teleflex LLC | $1,543.98 | 2021-2022 | |
| Boston Scientific Corporation | $557.78 | 2023-2025 | Lumenis Pulse 120h, General - Therapies, Axonics |
| Astellas Pharma US INC | $338.54 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $297.19 | 2022-2024 | Xiaflex, Aveed, Edex |
| Neotract INC. | $248.05 | 2019 | |
| Endo USA, INC. | $188.30 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $168.35 | 2025 | Gemtesa |
| Pfizer INC. | $162.18 | 2019-2021 | |
| Medtronic, INC. | $159.29 | 2021 | |
| Urogen Pharma, INC. | $149.96 | 2023 | Jelmyto |
| Medtronic USA, INC. | $138.78 | 2020 | |
| Calyxo, INC. | $135.15 | 2024 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $70.69 | 2020 | |
| Abbvie INC. | $57.67 | 2023-2025 | Botox |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.02 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Antares Pharma, INC. | $23.05 | 2019 | |
| Progenics Pharmaceuticals, INC. | $21.45 | 2025 | |
| Allergan, INC. | $16.90 | 2021 | |
| Amgen INC. | $15.05 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $12.35 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,109.49 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.